A big welcome from the Access Infinity team to our new Head if Engineering, Sriram Iyer. We all look forward to learning from your wealth of technology experience.
#welcome#welcometotheteam#teamwork#marketaccess
If you want to build your career in market access, how would you do it?
Click on this link to learn about the 5 steps to market access mastery:
🔗 https://t.co/Aw6szyjRDB
#AccessInfinity#pharmaconsulting#marketaccess
Please join us in welcoming Tim Wright to #AccessInfinity as Partner!
Tim brings 30 years of pricing, reimbursement and market access experience gained from senior executive positions in both global consultancy and the biopharmaceutical sector.
#marketaccess#pharma#consulting
Access Infinity is recruiting for a Project Manager to join our SMART Tools team. Developing cloud-based apps to support market access in Pharma. Follow the link below to learn about the role and apply.
#Recruiting#pharma#marketaccess#consulting
https://t.co/HgYSopirbU
Merry Christmas from the Access Infinity team.
2020 has been a challenging year for all, we are closing it with a bang and going virtual for Christmas with SMART Christmas parties
How are you making Christmas covid-safe?
#christmas2020#covidchristmas#martketaccess#pharma
IT'S ON! #PPMAConf virtual event starts today!
Login and join the first day of the World Leading Biopharma Pricing, Access and Evidence Congress from wherever you are!
💻 https://t.co/C3aiVKFUVQ
#PPMAConf
Fascinating. TB and peptic ulcers displaced by HT/CVS, HIV, obesity etc. Watch as new conditions muscle up the rankings. What drives this? So many factors- what's your list?
Death by a Thousand Clicks: Where Electronic Health Records Went Wrong. A great overview of the disaster of current EHRs and how we got here through government rushing the system. A huge cause of error and Physician burn out. #pathologists#ehr https://t.co/VdR6aA3n80
Cancer drug prices are not high because of high R&D costs; R&D costs are high because drug prices are high. https://t.co/I28CzZGWrP Input based cost-plus pricing for cancer drugs not the answer to accessibility. Payers need to become smarter negotiators. https://t.co/P6ognYP4fL
Very interesting panel discussion this morning at #ppmaconf this morning on "Achieving Greater Collaboration Amongst Payers, HTAs, Pharma and Patients to Improve Access and Pricing"looking forward to more lectures this afternoon.
@totalbiopharma
Day two of #ppmaconf is well and truly underway! Find us at booth 10 for more information on our SMART Tools as well as our consulting services and expertise on the Chinese market. Don't forget to pick up your free merchandise! @totalbiopharma#pharmapricing#freegiveaways
Day one at #ppmaconf has certainly been a success. We're very much looking forward to day two, meet us at booth 10 tomorrow to discuss our SMART tools and consulting expertise. Don't forget to pick up your free merchandise too!
@totalbiopharma#pharmapricing#AccessInfinity